Kynamro Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of genetic lipid disorders, regulatory approvals for antisense therapies, unmet needs in HoFH management, expansion of specialty lipid clinics, growing awareness of cardiovascular risk.

The growth in the forecast period can be attributed to replacement by next-generation lipid therapies, increased competition from novel biologics, expansion of genetic screening programs, rising focus on personalized cardiovascular care, broader access to specialty medicines. Major trends in the forecast period include increasing use of targeted lipid-lowering therapies, expansion of rare disease treatment protocols, growing adoption of injectable cholesterol therapies, enhanced focus on patient adherence solutions, rising integration with combination lipid therapies.

The increasing prevalence of cardiovascular disease is expected to propel the growth of the kynamro market going forward. Cardiovascular disease includes a range of conditions that affect the heart and blood vessels, often leading to complications such as heart attacks, strokes, and high blood pressure. The prevalence of these conditions is rising due to factors such as unhealthy dietary habits, limited physical activity, smoking, excessive alcohol intake, and increasing rates of obesity and diabetes. Kynamro supports cardiovascular health by reducing the production of a protein responsible for cholesterol accumulation, helping lower cholesterol levels and decreasing the long-term risk of heart-related complications. For instance, in September 2025, according to the British Heart Foundation, a UK-based cardiovascular research charity, there could be an additional one million people living with cardiovascular disease in the UK by 2030, rising to two million more than today by 2040. Therefore, the increasing prevalence of cardiovascular disease is driving the kynamro market growth.

The rise in personalized medicine is set to propel the growth of the Kynamro market moving forward. Personalized medicine refers to a medical approach that customizes healthcare treatments based on an individual's unique genetic makeup, environment, and lifestyle. The demand for personalized therapies is attributed to factors such as advancements in genetic research, a better understanding of diseases at the molecular level, and improved diagnostic tools. Kynamro serves as a personalized medicine by offering a targeted treatment for individuals with homozygous familial hypercholesterolemia (HoFH), directly addressing the genetic cause of elevated LDL cholesterol. This tailored approach enhances cholesterol management, particularly for patients who do not respond to conventional therapies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, marking a substantial rise from the six approvals in 2022. Therefore, the rise in personalized medicine is driving the growth of the kynamro market.

The rising prevalence of hypercholesterolemia is significantly driving the growth of the kynamro market in the future. Hypercholesterolemia refers to a medical condition characterized by abnormally high levels of cholesterol in the blood. Hypercholesterolemia rises due to factors such as genetic conditions, unhealthy diet, lack of physical activity, diabetes, and hypothyroidism. Kynamro effectively reduces LDL cholesterol levels in patients with familial hypercholesterolemia or those inadequately controlled by other treatments, making it highly beneficial for managing hypercholesterolemia. For instance, in July 2025, according to a study published in PubMed, a US-based international database managed by the National Library of Medicine, New therapies, such as PCSK9 inhibitors, demonstrated an increase from 33% in the first half of 2023 to 40% in the first half of 2024. Therefore, the rising prevalence of hypercholesterolemia is driving the growth of the kynamro market.

Major companies operating in the kynamro market are Ionis Pharmaceuticals Inc.

North America was the largest region in the kynamro market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kynamro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kynamro market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the kynamro market by increasing costs of imported active pharmaceutical ingredients, specialized syringes, cold-chain logistics equipment, and quality testing materials. North America and Europe are most affected due to dependence on imported antisense manufacturing inputs, while Asia-Pacific faces cost pressures related to API sourcing. These tariffs are increasing production and distribution costs for specialty lipid therapies. At the same time, they are encouraging localized API manufacturing, regional formulation capabilities, and supply chain diversification for rare disease treatments.

The kynamro market research report is one of a series of new reports that provides kynamro market statistics, including kynamro industry global market size, regional shares, competitors with a kynamro market share, detailed kynamro market segments, market trends and opportunities, and any further data you may need to thrive in the kynamro industry. This kynamro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kynamro is a medication designed to treat individuals with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes dangerously high cholesterol levels. It works by inhibiting the production of apolipoprotein B-100, a key protein required for the formation of low-density lipoprotein (LDL) cholesterol. By reducing LDL cholesterol, Kynamro helps manage cholesterol levels in patients who have not achieved sufficient control through other treatments. It is used alongside other lipid-lowering therapies to improve cholesterol management in these patients.

The main types of kynamro formulation are injectable formulation (subcutaneous) and pre-filled syringes or auto-injectors. The injectable subcutaneous formulation allows for consistent, controlled drug release, offering convenience for self-administration in patients with genetic cholesterol conditions. It is applicable in various indications, such as the treatment of homozygous familial hypercholesterolemia (HoFH), management of elevated LDL-C levels, and others for several patient demographics, including pediatric patients, adult patients, and geriatric patients. It is distributed through various distribution channels, such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and is used by several end users, including hospitals, specialty clinics, cardiovascular treatment centers, and home healthcare providers.

The kynamro market consists of sales of kynamro vials, syringes, needles, and mipomersen sodium (active ingredient). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.